Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040872 · ClinicalTrials.gov registry record · Phase 2
Multiple Therapies in Treating Patients With Advanced Neuroblastoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00040872: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00040872 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040872, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining different types of therapies may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy, monoclonal antibody therapy, surgery, peripheral stem cell transplantation, radiation therapy, and biological therapy in treating patients who have advanced neuroblastoma.
Interventions
- DRUG cisplatin
- DRUG carboplatin
- BIOLOGICAL filgrastim
- BIOLOGICAL sargramostim
- BIOLOGICAL monoclonal antibody 3F8
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00040872 record still lists
NCT00040872 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00040872 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00040872 about?
NCT00040872 is a clinical study titled "Multiple Therapies in Treating Patients With Advanced Neuroblastoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Monoclonal antibodies ca...
What is the current status of trial NCT00040872?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00040872?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), filgrastim (BIOLOGICAL), sargramostim (BIOLOGICAL), monoclonal antibody 3F8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00040872?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia